Back to today’s briefing

Story perspectives

Novo Nordisk, Eli Lilly Overcome Drug Shortages with Billions

1/5/2025

28 3

Summary

Story summary

Novo Nordisk and Eli Lilly have triumphantly tackled supply shortages of their GLP-1 diabetes and obesity medications, pouring billions into expanding manufacturing. With their products now off the FDA's shortage list, analysts foresee heightened competition from compounding pharmacies and stress the need for meticulous production planning for future developers in the metabolic drug arena.

1 of 1

Story summary

Novo Nordisk and Eli Lilly have triumphantly tackled supply shortages of their GLP-1 diabetes and obesity medications, pouring billions into expanding manufacturing. With their products now off the FDA's shortage list, analysts foresee heightened competition from compounding pharmacies and stress the need for meticulous production planning for future developers in the metabolic drug arena.